<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201601238768N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2016-10-09</date_registration>
      <primary_sponsor>Vice chancellor for Research and Technology, Hamadan University Of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the effect of phenylephrine on spinal anesthesia induced hypotension in cesarean section</public_title>
      <acronym></acronym>
      <scientific_title>Comparison between different prophylactic &amp; therapeutic phenylephrine regimenes in reducing maternal hypotention after induction of spinal anesthesia in caesarean section</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2016-10-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/9259</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>2-3</phase>
      <hc_freetext>spinal anesthesia induced hypotension.</hc_freetext>
      <i_freetext>Intervention 1: Intervention1: after performing spinal anesthesia (with 10 milligram bupivacaine plus 25 micro-gram fentanyl) 100 microgram phenylephrin in 1 cc volume will be injected  and then infusion of normal saline will be started and continued until delivery. In the case of hypotension 50 microgram phenylephrine will be injected. Intervention 2: Intervention 2:     after performing spinal anesthesia (with 10 milligram bupivacaine plus 25 micro-gram fentanyl) normal saline in 1 cc volume will be injected and then infusion of phenylephrine 50 microgram per minute  will be started and continued until delivery. In the case of hypotension 50 microgram phenylephrine will be injected. Intervention 3: Control group: after performing spinal anesthesia (with 10 milligram bupivacaine plus 25 micro-gram fentanyl) normal saline in 1 cc volume will be injected and then infusion of normal saline  will be started and continued until delivery. In the case of hypotension 50 microgram phenylephrine will be injected.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mahshid Nikooseresht M.D</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Anesthesiolgy Department, Besat hospital, Shahid Motahari Blvd, Resalat Square, Hamadan</address>
        <city>Hamadan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6514845471</zip>
        <telephone>+98 81 3264 0049</telephone>
        <email>nikooseresht@umsha.ac.ir</email>
        <affiliation>Hamadan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mahshid Nikooseresht M.D</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Anesthesiolgy Department, Besat Hospital, Shahid Motahari Blvd, Resalat Square, Hamadan</address>
        <city>Hamadan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6514845471</zip>
        <telephone>+98 81 3264 0050</telephone>
        <email>nikooseresht@umsha.ac.ir</email>
        <affiliation>Hamadan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: All of the ASA 1 healthy term  parturients referring to Fatemieh hospital candidate for Cesarean section were included in the study.&#13;
Exclusion criteria: chronic hypertension; pre eclampsia; twin pregnancy;, preterm labor; allergy to drugs; cardiovascular disease; renal disease and previous  abdominal surgeries with adhesion band and fibrosis.</inclusion_criteria>
      <agemin>16 years</agemin>
      <agemax>50 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>O74.6</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other complications of spinal and epidural anaesthesia during labour and delivery</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention1: after performing spinal anesthesia (with 10 milligram bupivacaine plus 25 micro-gram fentanyl) 100 microgram phenylephrin in 1 cc volume will be injected  and then infusion of normal saline will be started and continued until delivery. In the case of hypotension 50 microgram phenylephrine will be injected.</i_keyword>
      <i_keyword>Intervention 2:     after performing spinal anesthesia (with 10 milligram bupivacaine plus 25 micro-gram fentanyl) normal saline in 1 cc volume will be injected and then infusion of phenylephrine 50 microgram per minute  will be started and continued until delivery. In the case of hypotension 50 microgram phenylephrine will be injected.</i_keyword>
      <i_keyword>Control group: after performing spinal anesthesia (with 10 milligram bupivacaine plus 25 micro-gram fentanyl) normal saline in 1 cc volume will be injected and then infusion of normal saline  will be started and continued until delivery. In the case of hypotension 50 microgram phenylephrine will be injected.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Spinal anesthesia induced blood pressure change. Timepoint: before performing spinal anesthesia, every 2 minutes until delivery and then every 5 minutes until the end of surgery. Method of measurement: blood pressure was measured with automatic blood pressure device and hypotension was defined as more than 20% decrease of BP compared to baseline.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Heart rate. Timepoint: before performing spinal anesthesia and then every 5 minutes until the end of surgery. Method of measurement: Electrocardiogram monitoring.</sec_outcome>
      <sec_outcome>Nausea. Timepoint: every 5 minutes until the end of surgery. Method of measurement: observation.</sec_outcome>
      <sec_outcome>Vomiting. Timepoint: every 5 minutes until the end of surgery. Method of measurement: observation.</sec_outcome>
      <sec_outcome>Rescue vasopressor dose. Timepoint: at the end of surgery. Method of measurement: measurement.</sec_outcome>
      <sec_outcome>Neonatal condition. Timepoint: at min 1 and 5. Method of measurement: Apgar score mesurements by observation and physical examination.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice chancellor for Research and Technology, Hamadan University Of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2016-01-23</approval_date>
        <contact_name>Committee of Ethics in Research, Hamadan University of Medical Sciences</contact_name>
        <contact_address>Hamadan University of Medical Sciences, Shahid Fahmideh Street, Hamadan Hamedan  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
